The Pharma Letter's news editor, Katie Osborne, talks to Dr Clive Dix, chief executive of British drug discovery and development company, C4X Discovery, about his career, his top tips for success, Brexit and more.
27 April 2017 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2017.
31 March 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that, at the General Meeting held earlier today in respect of its £7.0m Placing at a Placing Price of 85 pence per new Ordinary Share, which was announced to the market on 14 March 2017, all the resolutions put to shareholders were duly passed.
1.30 p.m. GMT, 14 March 2017 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, is pleased to announce the completion of the Placing announced earlier today.
A total of 8,235,294 Placing Shares have been placed by Panmure Gordon (UK) Limited at a Placing Price of 85 pence per new Ordinary Share to raise a total of approximately £7.0 million for the Company (before expenses). The Placing Shares being issued represent approximately 22.0 per cent. of the issued ordinary share capital of the Company prior to the Placing. The Placing Price represents a discount of 7.1 per cent. to the Company's mid-market closing price as at 13 March 2017, being the last practicable day before the announcement of the Placing.
The net proceeds of the Placing receivable by the Company will be used to support the execution of its strategy of becoming the world's most productive, self-sustaining drug discovery engine by strengthening its balance sheet as partnering discussions and strategic collaborations progress, expanding its commercial capability and supporting working capital during the expansion of its pipeline portfolio.
22 November, 2016 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Brad Hoy, Chief Financial Officer (CFO), and Dr Craig Fox, Chief Scientific Officer (CSO), will join the Board of Directors with immediate effect. In addition, Brad Hoy has been appointed permanent CFO today following a period as interim CFO.
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that the Company has entered into a multi-target, risk-sharing alliance ("the Agreement") with Evotec AG ("Evotec"), a leading drug discovery alliance and development partnership company. The new Agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development, with the initial programmes targeted towards the treatment of cancer and autoimmune diseases.